* 2016 sales estimate for dexpramipexole was $350 mln
* Biogen to continue studying ALS treatments (Adds ALS Association, Biogen comment, study details, updates shares)
Jan 3 (Reuters) - An experimental drug to combat amyotrophic lateral sclerosis, commonly called Lou Gehrig's disease in the United States, failed to work in an important trial and Biogen Idec said it would stop development of the treatment.
The drug, dexpramipexole, had shown promise and seemed to work against ALS in a mid-stage clinical trial in 2011, creating hope for patients suffering from the progressive, fatal disease, who currently have few options.
Biogen shares, which rose 25 percent in 2012, fell 2 percent.
"There was a lot of hope behind this particular treatment," said Carrie Martin Munk, a spokeswoman for The ALS Association.
"Other companies are presently developing treatments to help fight ALS, so while we are saddened by today's news and had obviously hoped for better results, we're going to keep working with companies to advance treatments and bring them to patients as soon as possible," Munk said.
ALS is a disease of nerve cells in the brain and spinal cord that affects about 30,000 Americans, according to The ALS Association. About 5,600 Americans each year are diagnosed with the disease, long associated with legendary New York Yankees baseball player Lou Gehrig, whose career was cut short by ALS. He died of the disease in 1941.
There is currently only one drug available to help people with ALS - Rilutek, or riluzole, made by Sanofi. It has been shown to prolong the life of people with ALS, who have a life expectancy of two to five years after diagnosis.
The news was an uncommon blow for a company that has had a steady drum beat of positive news over the past few years.
Mark Schoenebaum, an analyst at ISI Group, said the failed study had been viewed as a high risk trial. Schoenebaum said Wall Street was estimating sales of about $350 million for the drug in 2016, but that he had figured on only about $100 million in sales by then.
In the 943-patient late-stage trial, dexpramipexole failed to slow decline of physical or respiratory function or improve survival, the company said. There was also no evidence of efficacy in subgroups of patients who were analyzed, leaving no path forward for the drug.
"We share the disappointment of members of the ALS community, who had hoped that dexpramipexole would offer a meaningful new treatment option," Biogen Executive Vice President of Research and Development Douglas Williams said in a statement.
Biogen said it is looking at other potential ALS treatments in preclinical programs and is working in collaboration with academic researchers at a variety of institutions.
"We're in it for the long run and we are committed to finding a treatment for ALS," Biogen spokeswoman Ligia Del Bianco said.
Biogen shares were down $3.10, or 2 percent, at $146.93 in late morning trading on Nasdaq. (Additional reporting by Caroline Humer in New York and Esha Dey in Bangalore; Editing by Roshni Menon, Nick Zieminski, John Wallace and Marguerita Choy)
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.